Physician profile
Daniel L Cottrell
NPI 1689073173
$2,236.55
in general payments reported to CMS, 2019-2025
29 companies · $510 in 2025
The $510 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $81.02 · 2022: $590 · 2023: $615 · 2024: $442 · 2025: $510.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,566.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,566.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $236.49 | 2022-2025 | |
| Pfizer INC. | $207.35 | 2023-2025 | |
| Dexcom, INC. | $150.53 | 2022-2025 | Dexcom G6 Transmitter |
| Lilly USA, LLC | $149.83 | 2022-2024 | Zepbound, Jardiance, Mounjaro |
| Astrazeneca Pharmaceuticals LP | $136.43 | 2022-2024 | Farxiga, Breztri, Airsupra |
| Organon LLC | $127.80 | 2021-2025 | Nexplanon |
| Boehringer Ingelheim Pharmaceuticals, INC. | $125.72 | 2022-2025 | Jardiance, Synjardy |
| Astellas Pharma US INC | $123.93 | 2022-2025 | Veozah |
| Johnson & Johnson Health Care Systems INC. | $121.72 | 2022 | |
| Novo Nordisk INC | $88.89 | 2021-2025 | Rybelsus, Ozempic |
| Abbott Laboratories | $84.62 | 2022-2025 | Freestyle Libre 3 |
| Sunovion Pharmaceuticals INC. | $63.19 | 2021-2022 | |
| Sumitomo Pharma America, INC. | $60.05 | 2023-2025 | Gemtesa |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $57.11 | 2022-2024 | Xifaxan |
| Glaxosmithkline, LLC. | $56.85 | 2023-2025 | Shingrix, Bexsero, Pediarix |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $52.01 | 2023-2024 | Repatha, Otezla |
| Dynavax Technologies Corporation | $51.59 | 2022-2025 | Heplisav-B |
| Biohaven Pharmaceutical Holding Company LTD. | $51.57 | 2022 | |
| Idorsia Pharmaceuticals US INC | $49.22 | 2023-2024 | Quviviq |
| Axsome Therapeutics, INC. | $49.07 | 2025 | Auvelity |
| Bayer Healthcare Pharmaceuticals INC. | $35.74 | 2025 | |
| Medtronic, INC. | $26.13 | 2022 | |
| Sanofi Pasteur INC. | $23.84 | 2023 | |
| Exact Sciences Corporation | $22.02 | 2023 | Cologuard Collection Kit |
| Sanofi-Aventis U.S. LLC | $20.36 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $19.91 | 2022 | |
| Genentech USA, INC. | $17.13 | 2022 | |
| Janssen Pharmaceuticals, INC | $13.85 | 2024 | Spravato |
| Merck Sharp & Dohme LLC | $13.60 | 2025 | Gardasil 9, Capvaxive |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Cottrell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.